# Antengene Corporation Limited
# 德琪醫藥有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6996)**

## VOLUNTARY ANNOUNCEMENT

## U.S. FDA IND CLEARANCE FOR PHASE I TRIAL OF SMALL MOLECULE ERK1/2 INHIBITOR ATG-017 IN PATIENTS WITH ADVANCED SOLID TUMORS

This announcement is made by Antengene Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group. The board of directors of the Company (the "**Board**") is pleased to announce that the Investigational New Drug ("**IND**") application for ATG-017 has received clearance from the U.S. Food and Drug Administration ("**FDA**"). The IND clearance enables the Company to initiate the combination portion of the Phase I "ERASER" clinical trial in the United States to evaluate the safety, pharmacokinetics, and preliminary efficacy of ATG-017 combination therapy with nivolumab in patients with advanced solid tumors.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ATG-017 will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By the order of the Board
**Antengene Corporation Limited**
**Dr. Jay Mei**
*Chairman*

Hong Kong, October 31, 2022

*As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Mr. Donald Andrew Lung and Dr. Kevin P. Lynch as executive directors; Mr. Yilun Liu and Dr. Kan Chen as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.*

**About ATG-017**

ATG-017 is an oral, potent, and selective small molecule extracellular signal-regulated kinases 1 and 2 (ERK1/2) inhibitor. ERK1/2 are related protein-serine/threonine kinases that function as terminal kinases in the RAS-MAPK signal transduction cascade. This cascade regulates a large variety of cellular processes, including proliferation. The RAS-MAPK pathway is dysregulated in more than 30% of human cancers with the most frequent alterations being observed in RAS or BRAF genes across multiple tumor types. An ERK inhibitor enables the targeting of both RAS and BRAF mutant diseases.

Antengene presented data at the Society for Immunotherapy in Cancer (SITC) 36th Annual Meeting & Pre-conference Programs in November 2021 detailing compelling preclinical results showing the combination of ATG-017 and an anti-PD-L1 monoclonal antibody (atezolizumab) in an aggressive immune checkpoint resistant murine cancer model rendered "cold" tumors "hot". To date, ATG-017 has been approved in Australia and the United States to enter clinical studies in patients with advanced solid tumors or hematologic malignancies.

**About Antengene**

Antengene Corporation Limited ("**Antengene**", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, driven by its vision of "Treating Patients Beyond Borders".

Since its founding in 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, including 10 assets with global rights and 5 with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 25 investigational new drug (IND) approvals in Asia and the U.S., and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in mainland China, Taiwan, South Korea, Singapore and Australia.

**Forward-looking statements**

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company's Annual Report for year-end December 31, 2021, and subsequent filings with the Hong Kong Stock Exchange.